Findings from a large-scale review indicate certain medications may influence dementia risk, offering insights for prevention and drug repurposing strategies.
With first drug now in the clinic, Alys eyes megaround for rest of pipeline
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
February 6, 2025